Phase III eXalt3 study shows ensartinib is far superior to crizotinib in ALK+ NSCLC

Recent interim results from the ongoing Phase III eXalt3 trial have shown that NSCLC patients with anaplastic lymphoma kinase (ALK) gene alterations experience a substantially longer progression-free survival (PFS) when treated with ensartinib over crizotinib (Xalkori ®). Presented at the International Association for the Study of Lung Cancer World Conference, the results show that NSCLC patients treated with ensartinib, a novel next-generation ALK tyrosine kinase inhibitor (TKI), resulted in a 2-fold increase in PFS when compared with crizotinib-treated patients. The results come from a planned interim analysis of the eXalt3 study following 75% of PFS events. The overall response rate...